Ranibizumab for myopic choroidal neovascularization

References

• Flitcroft DI, He M, Jonas JB, et al. IMI-defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019;60(3):M20–M30.
   PubMed Web of Science ®Google Scholar
• Pierro L, Camesasca FI, Mischi M, et al. Peripheral retinal changes and axial myopia. Retina. 1992;12:12–17.
   PubMed Web of Science ®Google Scholar
• Avila MP, Weiter JJ, Jalkh AE, et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology. 1984;91:1573–1581.
   PubMed Web of Science ®Google Scholar
• Neelam K, Cheung CM, Ohno-Matsui K, et al. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012;31:495–525.
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Green WR. Pathological findings in pathologic myopia. Retina. 1992;12:127–133.
   PubMed Web of Science ®Google Scholar
• Curtin BJ, Karlin DB. Axial length measurement and fundus changes of the myopic eyes. Am J Ophthalmol. 1979;71:42–50.
   Google Scholar
• Ohno-Matsui K, Yoshida T, Futagami S. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathologic myopia. Br J Ophthalmol. 2003;87:570–573.
   PubMed Web of Science ®Google Scholar
• Wong TY, Ferreira A, Hughes R, et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157:9–25.e12.
   PubMed Web of Science ®Google Scholar
• Cohen SY, Laroche A, Leguen Y, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103:1241–1244.
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Kawasaki R, Jonas JB, et al. International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol. 2015;159:877–83.e7.
   PubMed Web of Science ®Google Scholar
• Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology. 1983;90:923–926.
   PubMed Web of Science ®Google Scholar
• Secretan M, Kuhn D, Soubrane G, et al. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol. 1997;7:307–316.
   PubMedGoogle Scholar
• Yoshida T, Ohno-Matsui K, Ohtake Y. Long-term visual prognosis of choroidal neovascularization in high myopia: comparison between age groups. Ophthalmology. 2002;109:712–719.
   PubMed Web of Science ®Google Scholar
• Wong TY, Ohno-Matsui K, Leveziel N, et al. Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol. 2015 Mar;99(3):289–296.
   PubMed Web of Science ®Google Scholar
• Kojima A, Ohno-Matsui K, Teramukai S, et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2006;244:1474–1479.
   PubMed Web of Science ®Google Scholar
• Lai TY. Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization: do we need more evidence? Retina. 2012;32(8):1443–1445.
   PubMed Web of Science ®Google Scholar
• Lai TY, Cheung CM. Myopic choroidal neovascularization: diagnosis and treatment. Retina. 2016;36:1614–1621.
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Ikuno Y, Lai TYY, et al. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res. 2018;63:92–106.
   PubMed Web of Science ®Google Scholar
• Chan WM, Ohji M, Lai TY, et al. Choroidal neovascularization in pathological myopia: an update in management. Br J Ophthalmol. 2005;89:1522–1529.
   PubMed Web of Science ®Google Scholar
• Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol. 2009;53:121–138.
   Web of Science ®Google Scholar
• Pece A, Serini P, Avanza P, et al. Degenerative myopia: recurrence of subretinal neovessels after laser photocoagulation. J Fr Ophthalmol. 1990;13:24–28.
   PubMedGoogle Scholar
• Ruiz-Moreno JM, Montero JA. Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol. 2002;12:117–122.
   PubMed Web of Science ®Google Scholar
• Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularization in pathologic myopia. Cochrane Database Syst Rev. 2005;19:CD004765.
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P, Papayannis A, et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol. 2010;128:437–442.
   PubMed Web of Science ®Google Scholar
• Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial- VIP Report 1. Ophthalmology. 2001;108:841–852.
   PubMed Web of Science ®Google Scholar
• Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report No. 3. Ophthalmology. 2003;110:667–673.
   PubMed Web of Science ®Google Scholar
• Giansanti F, Virgili G, Donati MC, et al. Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia. Retina. 2012;32:1547–1552.
   PubMed Web of Science ®Google Scholar
• Chan WM, Lai TY, Chan KP, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina. 2008;28:1308–1313.
   PubMed Web of Science ®Google Scholar
• Lai TYY, Staurenghi G, Lanzetta P, et al. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina. 2018;38:1464–1477.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang T, Xu G, et al. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev. 2016 Dec 15;12(12):CD011160.
   PubMedGoogle Scholar
• Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859–870.
   PubMed Web of Science ®Google Scholar
• Rodrigues EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28:117–144.
   PubMed Web of Science ®Google Scholar
• Palmer BF, Clegg DJ. Oxygen sensing and metabolic homeostasis. Mol Cell Endocrinol. 2014;397:51–58.
   PubMed Web of Science ®Google Scholar
• Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536–544.
   PubMed Web of Science ®Google Scholar
• Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond). 2011;25(6):661–672.
   PubMed Web of Science ®Google Scholar
• Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res. 2002;64:162–169.
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Nagy JA, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol. 1999;237:97–132.
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–185.
   PubMed Web of Science ®Google Scholar
• Costagliola C, Semeraro F, dell’Omo R, et al. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation. Br J Ophthalmol. 2015;99:1004–1008.
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007;27:1260–1266.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179–2182.
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726–733.
   PubMed Web of Science ®Google Scholar
• Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci. 2013;5(54):1616–1624.
   Google Scholar
• Wochner RD, Strober W, Waldmann TA. The role of the kidney in the catabolism of bence jones proteins and immunoglobulin fragments. J Exp Med. 1967;126:207–221.
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645–2668.
   PubMed Web of Science ®Google Scholar
• Tufail A, Patel PJ, Sivaprasad S, et al. Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond). 2013;27:709–715.
   PubMed Web of Science ®Google Scholar
• Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013;120:1944–1945e1.
   PubMed Web of Science ®Google Scholar
• Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121:682–692e2.
   PubMed Web of Science ®Google Scholar
• Holz FG, Tufail A, Leveziel N, et al. Ranibizumab in myopic choroidal neovascularization: a subgroup analysis by ethnicity, age, and ocular characteristics in RADIANCE. Ophthalmologica. 2016;236:19–28.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sharma T, Li X, et al. Ranibizumab versus verteporfin photodynamic therapy in asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-month, randomized, double-masked study. Retina. 2019;39:1985–1994.
   PubMed Web of Science ®Google Scholar
• Tan NW, Ohno-Matsui K, Koh HJ, et al. Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in East-Asian patients from the RADIANCE study. Retina. 2018;38:2228–2238.
   PubMed Web of Science ®Google Scholar
• Hamilton RD, Clemens A, Minnella AM, et al. Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: results from the LUMINOUS study. PLoS One. 2020;15(1):e0227557.
   PubMed Web of Science ®Google Scholar
• Claxton L, Malcolm B, Taylor M, et al. Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK. Drugs Aging. 2014;31:837–848.
   PubMed Web of Science ®Google Scholar
• Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR Study. Ophthalmology. 2015;122:1220–1227.
   PubMed Web of Science ®Google Scholar
• Korol A, Kustryn T, Zadorozhnyy O, et al. Comparison of efficacy of intravitreal ranibizumab and aflibercept in eyes with myopic choroidal neovascularization: 24-month follow-up. J Ocul Pharmacol Ther. 2020;36:122–125.
   PubMed Web of Science ®Google Scholar
• Sayanagi K, Uematsu S, Hara C, et al. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2019;257:749–757.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang S, Yuan Y, et al. Progression and new onset of macular retinoschisis in myopic choroidal neovascularization eyes after conbercept therapy: a post-hoc analysis. Eye (Lond). 2020;34:523–529.
   PubMed Web of Science ®Google Scholar
• Chen C, Yan M, Huang Z, et al. The evaluation of a two-year outcome of intravitreal conbercept versus ranibizumab for pathological myopic choroidal neovascularization. Curr Eye Res. 2020;12:1-7.
   Web of Science ®Google Scholar
• Lai TY, Luk FO, Lee GK, et al. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond). 2012;26:1004–1011.
   PubMed Web of Science ®Google Scholar
• Kasahara K, Moriyama M, Morohoshi K, et al. Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia. Retina. 2017;37:1055–1064.
   PubMed Web of Science ®Google Scholar
• Braimah IZ, Stewart M, Videkar C, et al. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration. Br J Ophthalmol. 2017;101:1201–1205.
   PubMed Web of Science ®Google Scholar
• Singh SR, Dogra A, Stewart M, et al. Intravitreal ziv-aflibercept: clinical effects and economic impact. Asia Pac J Ophthalmol (Phila). 2017;6:561–568.
   PubMed Web of Science ®Google Scholar
• Hu Q, Li H, Du Y, et al. Comparison of intravitreal bevacizumab and ranibizumab used for myopic choroidal neovascularization: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98:e14905.
   PubMed Web of Science ®Google Scholar
• Iacono P, Parodi MB, Papayannis A, et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina. 2012;32:1539–1546.
   PubMed Web of Science ®Google Scholar
• Sharma A, Reddy P, Kuppermann BD, et al. Biosimilars in ophthalmology: “Is there a big change on the horizon?”. Clin Ophthalmol. 2018;12:2137–2143.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Das A, Do DV, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127:963–976.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: 96-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020 Jun 20;S0161-6420(20):30570–30574.
   Google Scholar
• Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology. 2020 Apr 25;S0161-6420(20):30371–30377.
   Google Scholar
• Rosenfeld PJ, Browning DJ. Is This a 737 Max Moment for Brolucizumab? [published online ahead of print. Am J Ophthalmol. 2020 May 25;S0002-9394(20):30242–30247.
   Google Scholar
• Hussain RM, Weng CY, Wykoff CC, et al. Abicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2020;20:999-1008.
   Web of Science ®Google Scholar
• Mullard A. FDA rejects first DARPin. Nat Rev Drug Dis. 2020 July 7. DOI:10.1038/d41573-020-00127-8.
   Web of Science ®Google Scholar
• Samanta A, Aziz AA, Jhingan M, et al. Emerging therapies in neovascular age-related macular degeneration in 2020. Asia Pac J Ophthalmol (Phila). 2020;9(3):250–259.
   PubMed Web of Science ®Google Scholar
• Otani A, Takagi H, Oh H, et al. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1912–1920.
   PubMed Web of Science ®Google Scholar
• Wu TT, Kung YH. Five-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization. Retina. 2017;37:2056–2061.
   PubMed Web of Science ®Google Scholar
• Onishi Y, Yokoi T, Kasahara K, et al. Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia. Retina. 2019;39:1289–1298.
   PubMed Web of Science ®Google Scholar
• Kang EC, Seo JG, Kim BR, et al. Clinical outcomes of intravitreal bevacizumab versus photodynamic therapy with or without bevacizumab for myopia choroidal neovascularization: a 7-year follow-up study. Retina. 2017;37:1775–1783.
   PubMed Web of Science ®Google Scholar
• Parravano M, Scarinci F, Gilardi M, et al. Patchy chorioretinal atrophy changes at the posterior pole after ranibizumab for myopic choroidal neovascularization. Invest Ophthalmol Vis Sci. 2017;58:6358–6364.
   PubMed Web of Science ®Google Scholar
• Saw SM, Matsumura S, Hoang QV. Prevention and management of myopia and myopic pathology. Invest Ophthalmol Vis Sci. 2019;60:488–499.
   PubMed Web of Science ®Google Scholar